NASDAQ · Biotechnology

BOLT (BOLT) Stock

$3.95 -0.50% NASDAQ: BOLT Healthcare

Valuation

MetricValue
Price$3.95
Market Cap$7.59M
P/E Ratio-0.26
P/B Ratio0.33
P/S Ratio1.36
EPS (TTM)$0.00
52-Week High$9.24
52-Week Low$3.78
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-122.22%
ROA-57.89%
ROCE-129.63%
Gross Margin-425.00%
Operating Margin-437.50%
Net Margin-4.55%
Debt/Equity1.13
Current Ratio3.75

Annual Financials (USD)

Metric20212022202320242025
Revenue$1.0M$6.0M$8.0M$8.0M$8.0M
Operating Profit$-93.0M$-90.0M$-76.0M$-73.0M$-35.0M
Net Profit$-99.0M$-88.0M$-69.0M$-63.0M$-33.0M
EPS$-2.79$-2.30$-1.83$-1.65$-17.85
Op Margin-7364.1%-1576.6%-967.5%-949.9%-450.1%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$308.0M$228.0M$160.0M$100.0M$57.0M
Total Liabilities$58.0M$56.0M$47.0M$42.0M$30.0M
Cash$27.0M$9.0M$11.0M$7.0M$12.0M
Borrowings$24.0M$23.0M$20.0M$25.0M$23.0M

Latest News

Metastatic HER2-Positive Breast Cancer Market Expected to Surge at a CAGR of 8.3% During the Forecast Period (2026–2036) Due to Advancing Targeted Treatments | DelveInsight GlobeNewswire · Jun 1, 2026 Bolt Biotherapeutics, Inc. (BOLT) Reports Q1 Loss, Lags Revenue Estimates Zacks · May 12, 2026 Bolt Biotherapeutics Inc.: Q1 Earnings Snapshot Associated Press · May 12, 2026 Bolt Biotherapeutics Reports First Quarter 2026 Financial Results and Provides Business Update GlobeNewswire · May 12, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-57.0M$-77.0M$-70.0M$-61.0M$-40.0M
Investing Cash Flow$-235.0M$56.0M$71.0M$58.0M$44.0M
Financing Cash Flow$0$0$0$0$0
Net Cash Flow$22.0M$-18.0M$2.0M$-4.0M$4.0M
Free Cash Flow$-59.0M$-78.0M$-70.0M$-61.0M$-40.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA—
FCF Yield-301.10%
Quick Ratio3.51
Interest Coverage—
Return 1Y-25.49%
Return 3Y-84.52%
Return 5Y-98.42%

Ownership

Insiders Held3.47%
Institutions Held28.86%
Institutions Float Held29.90%
Institutional HolderSharesReport Date
Sofinnova Investments, Inc.137,7212026-03-31
Renaissance Technologies, LLC77,2252026-03-31
Vivo Capital, LLC72,4142026-03-31
Pivotal bioVenture Partners Investment Advisor, LLC42,5812026-03-31
T3 Companies, LLC38,0002026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AEONAEON Biopharma, Inc. $0.24 -5.50% -0.05 $2.80M 0.00%
CING $4.52 -2.59% -1.08 $25.34M 0.00%
CLRB $2.37 -2.07% -0.38 $7.57M 0.00%
EVGNEvogene Ltd. $0.54 -0.04% -0.41 $4.67M 0.00%
IMNN $1.53 +0.00% -0.31 $3.86M 0.00%

About BOLT

BOLT is led by CEO William Quinn, employs 52 people, headquartered in US, publicly traded since 2021.

BOLT stock trades at $3.95 with a market capitalization of $7.59M. The stock is valued at a price-to-earnings (P/E) ratio of -0.26, price-to-book of 0.33, price-to-sales of 1.36. Over the past 52 weeks the stock has ranged between $3.78 and $9.24, and currently trades 57.3% below its 52-week high.

On profitability, BOLT generates a return on equity (ROE) of -122.22%, return on capital employed of -129.63%, an operating margin of -437.50%, a net profit margin of -4.55%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides